RATIONALE: A documented penicillin allergy is associated with increased alternative antibiotic exposures and related adverse events. We assessed beta-lactam test dose procedures prompted by an electronic guideline for inpatients with reported beta-lactam allergies in a large healthcare system. METHODS: We considered beta-lactam test dose procedures performed at two academic and three community Partners HealthCare System hospitals from September 2016 through December 2017. Patient history and test dose outcomes, including hypersensitivity reactions (HSRs) and allergy electronic health record (EHR) changes, were identified. HSR predictors were examined using a multivariable logistic regression model. RESULTS: 1,046 test dose procedures were included: 808 (77%) to cephalosporins, 149 (14%) to penicillins, and 89 (9%) to carbapenems. Test dose procedures were commonly performed at academic sites (83%), on internal medicine (45%), and ordered by housestaff providers (59%). Overall, 78 patients (7%) had signs or symptoms of an adverse reaction, with 40 (4%) consistent with HSRs. Most HSRs occurred at the full dose step (68%) and required no treatment beyond drug discontinuation (58%); 3 HSR patients were treated with epinephrine. Reported cephalosporin allergy history was associated with an increased HSR odds (aOR 2.96 [95% CI 1.34, 6.58]). Allergies were updated for 474 (45%) patients, with records specified (82%), deleted (16%), and added (8%). CONCLUSIONS: 4% of hospitalized patients with beta-lactam allergy histories receiving guideline-driven beta-lactam test dose procedures had an HSR, and cephalosporin allergy histories conferred a 3-fold increased risk. Allergy records were updated less than half of the time after challenge procedures, suggesting additional education and/or EHR prompting is needed.
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Nasal polyposis is a risk factor for having positive lysine-aspirin nasal challenges in aspirinexacerbated respiratory disease Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA, M alaga, Spain. RATIONALE: Aspirin-exacerbated respiratory disease (AERD) is a disorder of polyposis, rhinitis, asthma, and respiratory reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). The diagnosis is based on the clinical history and NSAIDs challenge, being nasal provocation test with lysine-aspirin (NPT-LASA) a safer and less time-consuming alternative than oral challenge. Our aim was to evaluate the potential factors related to positive results in NPT-LASA. METHODS: We performed NPT-LASA in 57 confirmed AERD subjects (> _3 episodes of respiratory manifestations with > _3 different NSAIDs or positive oral challenge with ASA). We also included 30 tolerant individuals to NSAIDs. We analyzed age, gender, underlying diseases, number of episodes, NSAIDs-induced symptoms, time interval of drug intake-reaction onset and last reaction-study in both negative and positive NPT-LASA cases. RESULTS: From 57 confirmed AERD subjects with a mean of 42.5 (25.75-55.25) years 73.7% were female. The 70.4% had underlying rhinitis, 63% asthma and 30.2% polyposis. The 66% were atopic and 66.7% non-smoker. The 52.7% experienced asthma after NSAIDs intake, 30.9% rhinitis/asthma, 5.4% throat tightness/asthma and 3.64% rhinitis and/or throat tightness. NPT-LASAwas positive in 45 patients and negative in all controls (sensitivity: 78.94%; specificity: 100%). The percentage of patients with nasal polyposis was higher in the group with NPT-LASA positive compared to those negative (50% vs 11.1% p50.002, OR58(1.923-33.274), p50.004). CONCLUSIONS: NPT-LASA shows a high sensitivity and specificity for diagnosing AERD, being the risk of having a positive NPT-LASA 8 times higher in patient with nasal polyposis.
